KENICHI FUJISE, M.D.
Osteopathic Medicine at Fannin St, Houston, TX
License number
Texas J3794
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Texas J3794
Category
Osteopathic Medicine
Type
Cardiovascular Disease
License number
Texas J3794
Category
Osteopathic Medicine
Type
Interventional Cardiology
Address
Address
6410 Fannin St, Houston, TX 77030
Phone
(832) 325-7211
(713) 500-3500
(713) 512-2245 (Fax)
(713) 500-3500
(713) 512-2245 (Fax)
Personal information
See more information about KENICHI FUJISE at radaris.comName
Address
Phone
7900 Cambridge St, Houston, TX 77054
6410 Fannin St, Houston, TX 77030
6411 Fannin St, Houston, TX 77030
Organization information
See more information about KENICHI FUJISE at bizstanding.comKenichi Fujise MD
6411 Fannin St, Houston, TX 77030
Industry:
Internist
Phone:
(713) 704-0900 (Phone)
Kenichi Fujise
Professional information
Dr. Kenichi Fujise - MD (Doctor of Medicine)
Hospitals:
2240 Gulf Fwy S Suite 2.100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
2240 Gulf Fwy S Suite 2.100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
2240 Gulf Fwy S Suite 2.100, League City 77573
UTMB Cardiology
301 University Blvd, Galveston 77555
Memorial Hermann - Texas Medical Center
6411 Fannin St, Houston 77030
Education:
Medical Schools
Kyoto University, Faculty Of Medicine
Graduated: 1987
Kyoto University, Faculty Of Medicine
Graduated: 1987
Kenichi Fujise, Galveston TX
Specialties:
Cardiologist
Address:
301 University Blvd, Galveston, TX 77555
6410 Fannin St, Houston, TX 77030
6410 Fannin St, Houston, TX 77030
Education:
Kyoto University, Faculty of Medicine - Doctor of Medicine
Metropolitan Hospital Center - Residency - Internal Medicine
Metropolitan Hospital Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine), American Board of Internal Medicine Sub-certificate in Interventional Cardiology (Internal Medicine)
Composition And Method For Treatment And Prevention Of Restenosis
US Patent:
2009002, Jan 22, 2009
Filed:
Aug 21, 2008
Appl. No.:
12/195735
Inventors:
Kenichi FUJISE - Houston TX, US
Zakar H. MNJOYAN - Houston TX, US
Zakar H. MNJOYAN - Houston TX, US
International Classification:
A61K 9/00, C12N 5/02, C07K 14/435, A61P 35/04, C12Q 1/68, A61K 38/16
US Classification:
424423, 435375, 530320, 514 12, 435 6
Abstract:
Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.
Composition And Method For Treatment And Prevention Of Restenosis
US Patent:
2004024, Dec 2, 2004
Filed:
May 30, 2003
Appl. No.:
10/448664
Inventors:
Kenichi Fujise - Houston TX, US
Zakar Mnjoyan - Houston TX, US
Zakar Mnjoyan - Houston TX, US
International Classification:
A61K038/17, C07K014/705
US Classification:
514/012000, 530/350000
Abstract:
Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.
Composition And Method For Treatment And Prevention Of Restenosis
US Patent:
2007005, Mar 8, 2007
Filed:
Aug 3, 2006
Appl. No.:
11/462106
Inventors:
Kenichi Fujise - Houston TX, US
Zakar Mnjoyan - Houston TX, US
Zakar Mnjoyan - Houston TX, US
Assignee:
BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX
International Classification:
A61K 38/17
US Classification:
514012000
Abstract:
Compositions and methods are disclosed which employ PARIS proteins that are useful for suppressing proliferation of smooth muscle cells. Preferred PARISs are soluble proteins that are secreted by vascular smooth muscle cells, and include PARIS-1 (neuronal pentraxin 1), PARIS-2 (SBP (MIC-1, GDF-15), PARIS-3 (BTG2) and PARIS-4 (soluble fractalkine). Methods of preventing or treating restenosis by administering the new compositions are disclosed. Also disclosed are methods for treating patients undergoing angioplasty procedures, patients with atherosclerosis, and patients with other proliferative disorders, in order to suppress the growth of vascular smooth muscle cells or other cells that play a role in the particular proliferative disorder or condition. A method of screening mRNAs and identifying genes encoding PARISs is also disclosed.